Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study
BUD/FORM delivered through Synchrobreathe<sup>®</sup> significantly improved CAT and mBDS scores, with no reported serious adverse events in patients with COPD. Its simple usage makes it an effective option for this patient population.
Authors
- Santhalingam Balamurugan
- Rajesh Swarnakar (ORCID: https://orcid.org/0000-0002-4993-6200)
- Deepak Talwar
- Raja Dhar (ORCID: https://orcid.org/0000-0002-6742-5674)
- Sheetu Singh (ORCID: https://orcid.org/0000-0003-3888-9856)
- Sujeet Rajan (ORCID: https://orcid.org/0000-0001-7955-2147)
- Abhijit Vaidya (ORCID: https://orcid.org/0000-0002-6046-9105)
- Vaishali Naik (ORCID: https://orcid.org/0000-0003-0923-2492)
- Sushmeeta Chhowala
- Utsav Samariya
- Jaideep Gogtay
- Komalkirti Apte
- Meena Lopez
- Himanshu Pophale
- Sandesh Sawant
Institutions
- Central University of Tibetan Studies (IN)
- ACS Medical College and Hospital (IN)
- National Heart Institute (IN)
- Maharashtra Association of Anthropological Sciences (IN)
- Cipla (India) (IN)
- Excell Research (United States) (US)
- Getwell Hospital and Research Institute (IN)
- Bhatia Hospital (IN)
- Rajasthan Dental College and Hospital (IN)
- AMRI Hospitals (IN)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1007/s40801-025-00522-w
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00